ZA200506504B - Liquid formulations of tumor necrosis factor-binding proteins - Google Patents
Liquid formulations of tumor necrosis factor-binding proteins Download PDFInfo
- Publication number
- ZA200506504B ZA200506504B ZA200506504A ZA200506504A ZA200506504B ZA 200506504 B ZA200506504 B ZA 200506504B ZA 200506504 A ZA200506504 A ZA 200506504A ZA 200506504 A ZA200506504 A ZA 200506504A ZA 200506504 B ZA200506504 B ZA 200506504B
- Authority
- ZA
- South Africa
- Prior art keywords
- tnf
- tumor necrosis
- necrosis factor
- formulation according
- receptor
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title description 5
- 102000019506 tumor necrosis factor binding proteins Human genes 0.000 title description 2
- 108091016215 tumor necrosis factor binding proteins Proteins 0.000 title description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 16
- 235000002639 sodium chloride Nutrition 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 108050001326 26S Proteasome regulatory subunit 6A Proteins 0.000 claims description 13
- 102100029510 26S proteasome regulatory subunit 6A Human genes 0.000 claims description 13
- 102000023732 binding proteins Human genes 0.000 claims description 10
- 108091008324 binding proteins Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- 239000013011 aqueous formulation Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229960002668 sodium chloride Drugs 0.000 claims description 3
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 claims 1
- 102400000091 Tumor necrosis factor-binding protein 2 Human genes 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 30
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 29
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 24
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 24
- 230000000694 effects Effects 0.000 description 11
- 229950010444 onercept Drugs 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108010003189 recombinant human tumor necrosis factor-binding protein-1 Proteins 0.000 description 10
- 239000011521 glass Substances 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940088679 drug related substance Drugs 0.000 description 7
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 6
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 6
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 6
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 6
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 5
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 5
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 5
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 5
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 5
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 5
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 5
- 102000057041 human TNF Human genes 0.000 description 5
- 102100027207 CD27 antigen Human genes 0.000 description 4
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 4
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 4
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 4
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 4
- 101710165474 Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 3
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 3
- 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 3
- 108010035042 Osteoprotegerin Proteins 0.000 description 3
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 3
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 3
- 108091007178 TNFRSF10A Proteins 0.000 description 3
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 3
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 Bromobutyl Chemical group 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 108010060408 Member 25 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 description 2
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 101710187887 Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 101710187751 Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 101150099875 atpE gene Proteins 0.000 description 2
- 101150018639 atpFH gene Proteins 0.000 description 2
- 101150048329 atpH gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229920005557 bromobutyl Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 230000010494 opalescence Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- OSNSWKAZFASRNG-WNFIKIDCSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical compound O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-WNFIKIDCSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 101100216285 Arabidopsis thaliana APO3 gene Proteins 0.000 description 1
- 241001415342 Ardea Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 108700002054 Glucocorticoid-Induced TNFR-Related Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 101100100117 Homo sapiens TNFRSF10B gene Proteins 0.000 description 1
- 101100046560 Homo sapiens TNFRSF14 gene Proteins 0.000 description 1
- 101100153525 Homo sapiens TNFRSF25 gene Proteins 0.000 description 1
- 101000648503 Homo sapiens Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 1
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
- 101000611185 Homo sapiens Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 101100098934 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) tbp2 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 101710178436 Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 description 1
- 101710187836 Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- CKRORYDHXIRZCH-UHFFFAOYSA-N phosphoric acid;dihydrate Chemical compound O.O.OP(O)(O)=O CKRORYDHXIRZCH-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000012602 primary packaging material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03100505 | 2003-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200506504B true ZA200506504B (en) | 2006-12-27 |
Family
ID=32921619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200506504A ZA200506504B (en) | 2003-02-28 | 2005-08-15 | Liquid formulations of tumor necrosis factor-binding proteins |
Country Status (22)
Country | Link |
---|---|
US (3) | US8937045B2 (pl) |
EP (1) | EP1603596B1 (pl) |
JP (1) | JP4980048B2 (pl) |
KR (1) | KR20050105486A (pl) |
CN (1) | CN100563712C (pl) |
AR (1) | AR043418A1 (pl) |
AT (1) | ATE394123T1 (pl) |
BR (1) | BRPI0407649A (pl) |
CA (1) | CA2515539A1 (pl) |
DE (1) | DE602004013557D1 (pl) |
EA (1) | EA009079B1 (pl) |
ES (1) | ES2304602T3 (pl) |
HK (1) | HK1085677A1 (pl) |
HR (1) | HRP20050706A2 (pl) |
IL (1) | IL170414A (pl) |
MX (1) | MXPA05009135A (pl) |
NO (1) | NO20054440L (pl) |
PL (1) | PL213501B1 (pl) |
RS (1) | RS51041B (pl) |
UA (1) | UA82503C2 (pl) |
WO (1) | WO2004075918A1 (pl) |
ZA (1) | ZA200506504B (pl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
TWI661833B (zh) * | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
TWI606840B (zh) | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
JP6463968B2 (ja) | 2011-07-01 | 2019-02-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法 |
AU2012326171B2 (en) * | 2011-10-18 | 2017-03-09 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
MX363226B (es) | 2011-10-31 | 2019-03-15 | Genentech Inc | Formulaciones de anticuerpos. |
CA2878508A1 (en) | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
EA031324B1 (ru) | 2012-09-11 | 2018-12-28 | Кохерус Байосайенсис, Инк. | Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода |
PL2919801T3 (pl) | 2012-10-26 | 2021-01-25 | Lupin Atlantis Holdings, Sa | Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu |
EP3162370A4 (en) | 2014-06-26 | 2017-11-15 | Maruishi Pharmaceutical Co., Ltd. | Rocuronium formulation with improved stability |
RU2724900C1 (ru) * | 2019-10-24 | 2020-06-26 | Маруиси Фармасьютикал Ко., Лтд. | Препарат рокурония с улучшенной стабильностью |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
AU670125B2 (en) * | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
EP0839046B1 (en) * | 1995-07-14 | 2002-01-23 | Applied Research Systems ARS Holding N.V. | Tnf receptor and steroid hormone dhea in a combined therapy |
HRP970224A2 (en) * | 1996-05-08 | 1998-04-30 | Hoffmann La Roche | TREATMENT OF ASTHMA WITH TNFR-Ig |
DK0942740T3 (da) * | 1996-12-06 | 2003-12-15 | Amgen Inc | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme |
US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
MXPA04008215A (es) * | 2002-02-27 | 2004-11-26 | Immunex Corp | Formulacion polipeptidica. |
-
2004
- 2004-02-11 JP JP2006502021A patent/JP4980048B2/ja not_active Expired - Fee Related
- 2004-02-11 EP EP04710041A patent/EP1603596B1/en not_active Expired - Lifetime
- 2004-02-11 AT AT04710041T patent/ATE394123T1/de not_active IP Right Cessation
- 2004-02-11 MX MXPA05009135A patent/MXPA05009135A/es active IP Right Grant
- 2004-02-11 ES ES04710041T patent/ES2304602T3/es not_active Expired - Lifetime
- 2004-02-11 EA EA200501230A patent/EA009079B1/ru not_active IP Right Cessation
- 2004-02-11 WO PCT/EP2004/050118 patent/WO2004075918A1/en active IP Right Grant
- 2004-02-11 RS YUP-2005/0662A patent/RS51041B/sr unknown
- 2004-02-11 KR KR1020057015762A patent/KR20050105486A/ko not_active Application Discontinuation
- 2004-02-11 CN CNB2004800103089A patent/CN100563712C/zh not_active Expired - Lifetime
- 2004-02-11 BR BRPI0407649-4A patent/BRPI0407649A/pt not_active IP Right Cessation
- 2004-02-11 CA CA002515539A patent/CA2515539A1/en not_active Abandoned
- 2004-02-11 PL PL378290A patent/PL213501B1/pl unknown
- 2004-02-11 DE DE602004013557T patent/DE602004013557D1/de not_active Expired - Lifetime
- 2004-02-11 US US10/547,307 patent/US8937045B2/en not_active Expired - Fee Related
- 2004-02-27 AR ARP040100618A patent/AR043418A1/es not_active Application Discontinuation
- 2004-11-02 UA UAA200508323A patent/UA82503C2/uk unknown
-
2005
- 2005-08-09 HR HR20050706A patent/HRP20050706A2/hr not_active Application Discontinuation
- 2005-08-15 ZA ZA200506504A patent/ZA200506504B/en unknown
- 2005-08-22 IL IL170414A patent/IL170414A/en active IP Right Grant
- 2005-09-26 NO NO20054440A patent/NO20054440L/no not_active Application Discontinuation
-
2006
- 2006-07-19 HK HK06108097.9A patent/HK1085677A1/xx not_active IP Right Cessation
-
2014
- 2014-12-15 US US14/570,244 patent/US9512215B2/en not_active Expired - Lifetime
-
2016
- 2016-09-30 US US15/283,001 patent/US20170020960A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA009079B1 (ru) | 2007-10-26 |
CA2515539A1 (en) | 2004-09-10 |
RS20050662A (en) | 2007-11-15 |
BRPI0407649A (pt) | 2006-02-21 |
HRP20050706A2 (en) | 2005-12-31 |
MXPA05009135A (es) | 2005-10-20 |
CN100563712C (zh) | 2009-12-02 |
EP1603596A1 (en) | 2005-12-14 |
IL170414A (en) | 2009-11-18 |
ES2304602T3 (es) | 2008-10-16 |
AU2004216483A1 (en) | 2004-09-10 |
US20170020960A1 (en) | 2017-01-26 |
UA82503C2 (uk) | 2008-04-25 |
HK1085677A1 (en) | 2006-09-01 |
US20070053906A1 (en) | 2007-03-08 |
US9512215B2 (en) | 2016-12-06 |
JP4980048B2 (ja) | 2012-07-18 |
US8937045B2 (en) | 2015-01-20 |
PL213501B1 (pl) | 2013-03-29 |
WO2004075918A1 (en) | 2004-09-10 |
JP2006519210A (ja) | 2006-08-24 |
AR043418A1 (es) | 2005-07-27 |
RS51041B (sr) | 2010-10-31 |
US20150098950A1 (en) | 2015-04-09 |
DE602004013557D1 (de) | 2008-06-19 |
ATE394123T1 (de) | 2008-05-15 |
EA200501230A1 (ru) | 2006-04-28 |
NO20054440L (no) | 2005-09-26 |
EP1603596B1 (en) | 2008-05-07 |
KR20050105486A (ko) | 2005-11-04 |
PL378290A1 (pl) | 2006-03-20 |
CN1774266A (zh) | 2006-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9512215B2 (en) | Liquid formulations of tumor necrosis factor-binding proteins | |
JP7260477B2 (ja) | Tigit及びlightベースのキメラタンパク質 | |
Idriss et al. | TNFα and the TNF receptor superfamily: Structure‐function relationship (s) | |
EP2699265B1 (en) | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc | |
AU2007307107B2 (en) | Stable antibody formulations | |
AU2007309616A1 (en) | Stable polypeptide formulations | |
EP2021030A2 (en) | Buffering agents for biopharmaceutical formulations | |
AU2007252295B2 (en) | Selective modulation of receptor signalling | |
KR20190133707A (ko) | 신테카인 조성물 및 사용방법 | |
EP3265477A2 (en) | Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases | |
Aggarwal et al. | Tumor necrosis factor | |
JP2024096361A (ja) | Flt3l系キメラタンパク質 | |
AU2004216483B2 (en) | Liquid formulations of tumor necrosis factor-binding proteins | |
AU2022387678A1 (en) | Sirp1a - and cd40l-based chimeric proteins | |
TW202313098A (zh) | 用於冠狀病毒感染之治療或預防的干擾素相聯抗原結合蛋白 | |
JP2017508792A5 (pl) | ||
Alexander et al. | Catalytic receptors | |
JP2017508792A (ja) | オステオプロテゲリンはランケル・インヒビターを引き出した |